| Literature DB >> 21572528 |
Neil R Hackett1, Renat Shaykhiev, Matthew S Walters, Rui Wang, Rachel K Zwick, Barbara Ferris, Bradley Witover, Jacqueline Salit, Ronald G Crystal.
Abstract
BACKGROUND: The human airway epithelium consists of 4 major cell types: ciliated, secretory, columnar and basal cells. During natural turnover and in response to injury, the airway basal cells function as stem/progenitor cells for the other airway cell types. The objective of this study is to better understand human airway epithelial basal cell biology by defining the gene expression signature of this cell population. METHODOLOGY/PRINCIPALEntities:
Mesh:
Year: 2011 PMID: 21572528 PMCID: PMC3087716 DOI: 10.1371/journal.pone.0018378
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Characterization of cultured human airway epithelial basal cells.
Large airway epithelial cells were collected by bronchoscopy brushing of healthy nonsmokers and cultured under basal cell-selective conditions for 7 to 8 days until 70% confluent. A–G. Confirmation of basal cell identity and purity by immunohistochemistry of cytospin preparations using cell type-specific markers. A. cytokeratin 5 (basal cells); B. TP63 (basal cells); C. CD151 (basal cells); D. chromagranin A (neuroendocrine cells) E. N-cadherin (mesenchymal cells); F. mucin (MUC) 5AC (secretory cells) and G. β-tubulin IV (ciliated cells). All cells were counterstained with Mayer's hematoxylin. H–K. Differentiation of basal cells on air-liquid interface cultures. H. Immunofluorscent staining for β-tubulin IV, day 0 (DAPI, nucleus). I. β-tubulin IV, day 28 (DAPI, nucleus; red, β-tubulin). J. Scanning electron microscopy at day 28. Scale bar for all panels A–J = 10 µm. K. Immunofluorescent staining of section of 28 day air liquid interface culture for β-tubulin (red) and cytokeratin 5 (green). L. Western analysis of basal and differentiated cell proteins probing equal amounts of extracts of basal cells from nonsmoker (BC-NS), large airway epithelium from a nonsmoker (LAE-NS), and large airway epithelium from a smoker (LAE-S) with antibodies as described in Methods section.
Figure 2Identification of basal cell-enriched transcripts.
A. Principal component analysis of gene expression of basal cells (n = 5; blue circles) and differentiated airway epithelium samples (n = 12; red circles) using all expressed gene probe sets (n = 39,324) as an input dataset. B. Hierarchical cluster analysis of basal cells (n = 5) compared to complete airway epithelium samples (n = 12) based on the expression of 1,000 randomly chosen probe sets detected in either of groups. Genes expressed above the average are represented in red, below average in blue, and average in white. The genes are represented vertically, and individual samples horizontally. C. Volcano plot comparing the transcriptomes of basal cells (n = 5) and complete airway epithelium (n = 12). In both panels, the y-axis corresponds to the negative log of p value and the x-axis corresponds to the log2-transformed fold-change. Red dots represent significant differentially expressed probe sets (fold-change >5; p value<0.01 with Benjamini-Hochberg correction); grey dots represent nonsignificant gene probe sets. D. Volcano plot assessing the transcriptome of basal cells vs complete large airway epithelium using a list of only ciliogenesis-related genes [29], [30]. E. Volcano plot assessing the transcriptomes of basal cell vs complete large airway epithelium using a list of only secretory cell-related genes [29]. F. Suppression of the basal cell-enriched transcriptome when basal cells are induced to differentiate into specialized airway cells in air-liquid interface culture. Pure populations of basal cells were plated onto air-liquid interface cultures and RNA was prepared on day 0 and day 28. The gene expression profile was determined and a cluster built using the genes of human airway basal cell-enriched transcriptome.
Top 45 Human Airway Basal Cell-enriched Genes.1
| Category | ProbeSetID | Gene symbol | Gene title | Mean expression in differentiated epithelium | Mean expression in basal cells | Basal/differentiated epithelium expression ratio | p value |
| Cytoskeleton | 209125_at | KRT6A | keratin 6A | 1.1 | 724.4 | 667.2 | 3.2×10−9 |
| 209800_at | KRT16 | keratin 16 | 0.1 | 88.7 | 635.4 | 2.7×10−8 | |
| 209126_x_at | KRT6B | keratin 6B | 1.8 | 353.0 | 196.2 | 3.6×1010 | |
| 209191_at | TUBB6 | tubulin, beta 6 | 1.1 | 142.5 | 127.8 | 4.0×10−4 | |
| 221870_at | EHD2 | EH-domain containing 2 | 0.3 | 33.1 | 123.7 | 1.1×10−8 | |
| 212077_at | CALD1 | caldesmon 1 | 1.2 | 135.8 | 109.6 | 1.2×10−5 | |
| 201564_s_at | FSCN1 | fascin homolog 1, actin-bundling protein | 0.3 | 26.9 | 89.0 | 1.3×10−5 | |
| Extracellular matrix | 204636_at | COL17A1 | collagen, type XVII, alpha 1 | 0.1 | 31.0 | 353.0 | 6.5×10−6 |
| 201656_at | ITGA6 | integrin, alpha 6 | 2.6 | 129.8 | 50.8 | 5.9×10−9 | |
| Protease/antiprotease | 222162_s_at | ADAMTS1 | ADAM metallopeptidase with thrombospondin type 1 motif, 1 | 0.1 | 43.1 | 327.7 | 4.8×10−5 |
| 205778_at | KLK7 | kallikrein-related peptidase 7 | 0.1 | 24.2 | 221.3 | 3.6×10−5 | |
| 205479_s_at | PLAU | plasminogen activator, urokinase | 0.9 | 113.5 | 132.0 | 3.8×10−3 | |
| 202628_s_at | SERPINE1 | serpin peptidase inhibitor, clade E, member 1 | 0.4 | 46.8 | 116.5 | 7.7×10−3 | |
| 212190_at | SERPINE2 | serpin peptidase inhibitor, clade E, member 2 | 0.9 | 85.0 | 91.4 | 1.9×10−9 | |
| Epidermal function | 206884_s_at | SCEL | sciellin | 0.4 | 73.3 | 194.6 | 2.0×10−7 |
| 213796_at | SPRR1A | small proline-rich protein 1A | 0.2 | 83.9 | 371.4 | 2.2×10−5 | |
| 205064_at | SPRR1B | small proline-rich protein 1B (cornifin) | 0.7 | 234.3 | 345.5 | 5.4×10−8 | |
| 205239_at | AREG | amphiregulin | 2.7 | 354.7 | 133.9 | 8.5×10−10 | |
| 232082_x_at | SPRR3 | small proline-rich protein 3 | 0.8 | 48.2 | 60.1 | 5.0×10−4 | |
| Signaling ligand | 205767_at | EREG | epiregulin | 0.1 | 34.6 | 246.0 | 8.0×10−7 |
| 206343_s_at | NRG1 | neuregulin 1 | 0.4 | 19.8 | 53.4 | 7.4×10−7 | |
| Signal transduction | 218309_at | CAMK2N1 | calcium/calmodulin-dependent protein kinase II inhibitor 1 | 0.6 | 51.0 | 85.4 | 3.0×10−7 |
| 204602_at | DKK1 | dickkopf homolog | 1.1 | 91.4 | 82.6 | 2.2×10−3 | |
| 210138_at | RGS20 | regulator of G-protein signaling 20 | 0.2 | 16.1 | 82.3 | 3.5×10−7 | |
| 203438_at | STC2 | stanniocalcin 2 | 0.1 | 21.1 | 277.1 | 2.6×10−7 | |
| 212097_at | CAV1 | caveolin 1, caveolae protein, 22 kDa | 1.0 | 177.4 | 169.5 | 1.0×10−3 | |
| 201109_s_at | THBS1 | thrombospondin 1 | 0.5 | 59.4 | 110.4 | 7.3×10−3 | |
| Transcription | 1555788_a_at | TRIB3 | tribbles homolog 3 (Drosophila) | 0.2 | 28.9 | 161.5 | 1.0×10−8 |
| 1552487_a_at | BNC1 | basonuclin 1 | 0.5 | 35.1 | 69.7 | 9.4×10−5 | |
| Metabolism | 203234_at | UPP1 | uridine phosphorylase 1 | 0.9 | 254.7 | 268.9 | 8.5×10−9 |
| 219181_at | LIPG | lipase, endothelial | 0.3 | 16.0 | 62.8 | 3.0×10−4 | |
| 231202_at | ALDH1L2 | Aldehyde dehydrogenase 1 family, member L2 | 0.3 | 24.3 | 79.9 | 2.1×10−5 | |
| 223062_s_at | PSAT1 | phosphoserine aminotransferase 1 | 4.3 | 233.0 | 54.5 | 1.0×10−8 | |
| Oxidation/reduction | 218717_s_at | LEPREL1 | leprecan-like 1 | 0.1 | 6.8 | 57.0 | 1.8×10−3 |
| Gap junction | 223278_at | GJB2 | gap junction protein, beta 2, 26 kDa | 3.3 | 183.1 | 56.2 | 4.0×10−3 |
| 231771_at | GJB6 | gap junction protein, beta 6, 30 kDa | 0.2 | 18.7 | 75.3 | 8.9×10−3 | |
| Cell adhesion | 235075_at | DSG3 | desmoglein 3 (pemphigus vulgaris antigen) | 0.5 | 114.9 | 222.2 | 5.5×10−5 |
| Apoptosis | 217996_at | PHLDA1 | pleckstrin homology-like domain, family A, member 1 | 1.8 | 112.3 | 61.2 | 1.8×10−5 |
| Immune responses | 207526_s_at | IL1RL1 | interleukin 1 receptor-like 1 | 0.2 | 106.3 | 449.9 | 7.0×10−4 |
| 206172_at | IL13RA2 | interleukin 13 receptor, alpha 2 | 0.2 | 32.9 | 200.8 | 9.0×10−4 | |
| 212657_s_at | IL1RN | interleukin 1 receptor antagonist | 2.1 | 162.7 | 77.6 | 3.0×10−4 | |
| Ion transport | 209900_s_at | SLC16A1 | solute carrier family 16, member 1 | 0.3 | 23.8 | 69.8 | 1.9×10−7 |
| 201195_s_at | SLC7A5 | solute carrier family 7, member 5 | 0.6 | 201.0 | 314.7 | 6.7×10−8 | |
| Unknown | 220620_at | CRCT1 | cysteine-rich C-terminal 1 | 0.2 | 16.9 | 97.4 | 7.0×10−4 |
The probe set with the highest basal/differentiated epithelium expression ratio for the top 45 enriched named genes.
BH – Benjamini-Hochberg.
Figure 3Principal component analysis-based comparison of airway basal cells to other human tissues and cells.
Compared tissues and cell types were all of human origin and included: basal cells (human airway basal cells, red; n = 5); differentiated epithelium (complete large airway epithelium obtained by brushing, green; n = 12); ALI-d0 (basal cells cultured on ALI until confluent, ∼2 days after plating (see Methods), grey; n = 3); ALI-d28 (the same airway basal cells after 28 days of differentiation in air-liquid interface, yellow; n = 3); breast stem cells (from Gene Expression Omnibus GSE15192: CD44+ CD24− stem-like fraction of MCF-10A immortalized breast epithelial cells, dark blue; n = 4), basal-like breast cancer (GSE3744: orange; n = 5); keratinocytes (GSE7216: primary neonatal foreskin epidermal keratinocytes, pink; n = 3); cervical cancer (GSE5993: p63-overexpressing cervical cancer cell line ME180; light blue; n = 3); and fibroblasts (GSE17032: human skin and lung fibroblasts, purple; n = 20). A. Analysis based on the entire transcriptome. B. Analysis based on the 1,161 genes of basal cell signature.
Figure 4Hierarchical mapping of Gene Ontology (GO) categories enriched in the human basal cell transcriptome.
Basal cell-enriched gene probe sets (n = 1,828) were used to generate a GO tree using GoSurfer software to display “biologic process” categories related to “cellular process” (left branch), “development” (middle branch) and “physiologic process” (right branch). Significantly enriched categories (p<10−10) are represented as red nodes; grey nodes represent mostly closely mapped nonsignificant categories; edges represent “parent-child” relationships of GO terms.
GATHER KEGG Pathway Analysis of the Human Airway Basal Cell-enriched Transcriptome.1
| KEGG pathways | Annotation | Gene number/total | % genes enriched | p value | Bayes factor |
| hsa04510 | Focal adhesion | 44/201 | 22 | 2×10−8 | 13 |
| hsa04512 | Extracellular matrix-receptor interaction | 18/84 | 21 | 0.0002 | 4 |
| hsa04520 | Adherens junction | 16/75 | 21 | 0.0006 | 3 |
| hsa04010 | MAPK signaling pathway | 32/271 | 12 | 0.004 | 1 |
| hsa04810 | Regulation of actin cytoskeleton | 29/216 | 13 | 0.005 | 1 |
GATHER (Gene Annotation Tool to Help Explain Relationships, http://gather.genome.duke.edu/) was used to assist in functional annotation of the human basal cell-specific transcriptome. Input data consisted of the unique named genes from probe sets with basal/large airway epithelium expression ratio >5, p<0.01 following Benjamini-Hochberg multiple test correction. For the KEGG pathways analysis, the significant pathways are shown.
Number of genes in that category represented in the human airway basal cell-enriched transcriptome/total genes in pathway.
A measure of false discovery rate; a Bayes factor ≥1 is significant.
GATHER GO Analysis of the Human Airway Basal Cell-enriched Transcriptome.1
| Gene ontology | Annotation | Gene number/total | % genes enriched | p value | Bayes factor |
| GO:0007398 | ectoderm development | 22/218 | 10.1 | 6.5×10−11 | 17.1 |
| GO:0008544 | epidermis development | 19/202 | 9.4 | 1.7×10−9 | 13.8 |
| GO:0000074 | regulation of cell cycle | 52/448 | 11.6 | 4.1×10−8 | 11.0 |
| GO:0009887 | organogenesis | 90/650 | 13.8 | 9.4×10−7 | 8.1 |
| GO:0009653 | morphogenesis | 106/1338 | 7.9 | 1.3×10−6 | 7.9 |
| GO:0008283 | cell proliferation | 98/1169 | 8.4 | 2.8×10−6 | 7.1 |
| GO:0009113 | purine base biosynthesis | 4/8 | 50.0 | 1.2×10−5 | 4.8 |
| GO:0030216 | keratinocyte differentiation | 5/75 | 6.7 | 3.3×10−5 | 3.8 |
| GO:0006144 | purine base metabolism | 4/15 | 26.7 | 5.6×10−5 | 3.3 |
| GO:0007049 | cell cycle | 66/1000 | 6.6 | 1.4×10−4 | 3.2 |
GATHER (Gene Annotation Tool to Help Explain Relationships, http://gather.genome.duke.edu/) was used to assist in functional annotation of the human basal cell-specific transcriptome. Input data consisted of the unique named genes from probe sets with basal/large airway epithelium expression ratio >5, p<0.01 following Benjamini-Hochberg multiple test correction. For the Gene Ontology analysis the top 10 genes are shown.
Number of genes in that category represented in the human airway basal cell-enriched transcriptome.
A measure of false discovery rate in which a positive number is significant; the GATHER analysis identified (n = 71) categories with Bayes factor ≥1; shown are the top 10 categories.
Canonical Pathways Dominant in Human Airway Epithelium Basal Cells Compared to the Differentiated Complete Airway Epithelium.1
| Pathway | Ratio (% of the total genes in pathway) | p value |
| Neuregulin signaling | 22/103 (21.4) | 1.9×10−7 |
| Integrin signaling | 33/202 (16.3) | 2.0×10−6 |
| ILK signaling | 31/186 (16.7) | 2.5×10−6 |
| Ephrin receptor signaling | 30/19 (18.2) | 6.3×10−6 |
| Virus entry via endocytic pathway | 19/96 (19.8) | 9.3×10−6 |
| Glioblastoma multiforme signaling | 26/163 (16.0) | 1.7×10−5 |
| HER2 signaling in breast cancer | 17/79 (21.5) | 2.2×10−5 |
| Renal cell carcinoma signaling | 16/72 (22.2) | 2.3×10−5 |
| Clatharin-mediated endocytosis signaling | 26/167 (15.6) | 4.9×10−5 |
| Agrin interactions at neuromuscular junction | 15/69 (21.7) | 7.6×10−5 |
Functional pathway analysis was carried out using Ingenuity Pathway Analysis (http://www.ingenuity.com) on all basal cell-enriched (fold basal/large airway epithelium ratio >5, p<0.01 following Benjamini-Hochberg multiple test correction).
The top 10 canonical pathways were selected on the basis of significance.
Ratio refers to the number of pathway genes in the basal cell-enriched signature dataset compared to the total number of genes in the curated pathway.
Extracellular Matrix and Cytoplasmic Structural Proteins in the Human Airway Basal Cell-enriched Signature.1
| Category | Genes | Mean expression in differentiated epithelium | Mean expression in basal cells | Basal/differentiated epithelium expression ratio |
|
| ||||
| Collagens | COL4A1 | 0.5 | 4.3 | 7.9 |
| COL4A2 | 0.7 | 5.1 | 7.2 | |
| COL4A6 | 5.1 | 39.3 | 7.6 | |
| COL7A1 | 1.1 | 15.9 | 15.1 | |
| COL12A1 | 0.4 | 4.0 | 9.7 | |
| COL17A1 | 0.1 | 31.0 | 353.0 | |
| Thrombospondin | ADAMTS1 | 0.1 | 43.1 | 327.7 |
| THBS1 | 0.5 | 59.4 | 110.4 | |
| Laminins | LAMA3 | 5.4 | 148.4 | 27.6 |
| LAMB1 | 1.8 | 31.3 | 17.3 | |
| LAMB3 | 15.9 | 297.3 | 18.7 | |
| LAMC1 | 3.5 | 45.0 | 12.9 | |
| LAMC2 | 11.8 | 417.2 | 35.2 | |
| Other | TNC | 8.6 | 118.0 | 13.7 |
| HSPG2 | 4.5 | 26.8 | 6.0 | |
| SDC1 | 12.0 | 110.9 | 9.3 | |
| CD44 | 5.9 | 58.2 | 9.9 | |
|
| ||||
| Integrins | ITGA3 | 3.2 | 50.1 | 15.8 |
| ITGA5 | 0.7 | 18.3 | 27.3 | |
| ITGA6 | 2.6 | 129.8 | 50.8 | |
| ITGB1 | 16.9 | 216.8 | 12.8 | |
| ITGB4 | 11.0 | 106.2 | 9.6 | |
| ITGB6 | 5.4 | 44.6 | 8.3 | |
|
| ||||
| Filamin and related | FLNA | 2.0 | 38.0 | 19.1 |
| FLNB | 13.4 | 103.5 | 7.7 | |
| FBLIM1 | 0.6 | 9.2 | 14.9 | |
| FILIP1L | 0.5 | 3.8 | 8.2 | |
| Vinculin | VCL | 9.6 | 55.8 | 5.8 |
| Actinins | ACTN1 | 4.2 | 70.8 | 17.0 |
|
| ||||
| G-proteins | RAC2 | 6.9 | 50.2 | 7.3 |
| RALA | 5.5 | 47.9 | 8.6 | |
| RAP2A | 6.9 | 37.0 | 5.4 | |
| RAP2B | 6.5 | 55.8 | 8.5 | |
| RHOC | 18.8 | 100.3 | 5.3 | |
| RHOD | 2.5 | 32.6 | 13.0 | |
| RHOF | 0.3 | 3.1 | 11.5 | |
| RRAS | 1.9 | 59.5 | 30.8 | |
|
| ||||
| Keratins | KRT34 | 0.1 | 0.6 | 7.8 |
| KRT17 | 10.7 | 537.9 | 50.3 | |
| KRT16 | 0.1 | 88.7 | 635.4 | |
| KRT7 | 15.6 | 117.8 | 7.6 | |
| KRT6B | 1.8 | 353.0 | 196.2 | |
| KRT6A | 1.1 | 724.4 | 667.2 | |
| KRT5 | 44.5 | 382.6 | 8.6 | |
| Other | ARPC2 | 27.7 | 187.1 | 6.8 |
| ARPC5L | 9.0 | 52.2 | 5.8 | |
| DSP | 69.6 | 359.2 | 5.2 | |
| MSN | 8.3 | 87.2 | 10.5 | |
| PLS3 | 24.5 | 221.7 | 9.1 | |
| DBN1 | 1.5 | 19.1 | 12.4 | |
Genes identified by GATHER KEGG categories (Table 2, Table S3), Gene Ontology categories (Table 3, Table S5), and/or Canonical Pathways (Table 4, Table S6).
Ligands in the Human Airway Basal Cell-enriched Transcriptome.1
| Ligand family | Genes | Mean expression in differentiated epithelium | Mean expression in basal cells | Basal/differentiated epithelium expression ratio |
| Vascular endothelial growth factors | VEGFA | 4.2 | 35.1 | 8.3 |
| VEGFC | 1.3 | 9.1 | 7.2 | |
| Angiopoietin | ANGPTL4 | 0.8 | 4.6 | 5.8 |
| Platelet derived growth factors | PDGFA | 3.0 | 19.4 | 6.4 |
| PDGFC | 12.7 | 78.6 | 6.2 | |
| Placental growth factor | PGF | 0.4 | 7.3 | 17.9 |
| Wingless-type MMTV integration site family | WNT7A | 0.2 | 2.9 | 15.7 |
| Bone morphogenic proteins | BMP1 | 0.4 | 5.2 | 12.3 |
| BMP2 | 0.3 | 8.2 | 30.7 | |
| GDF15 | 13.6 | 135.2 | 10.0 | |
| Transforming growth factors | TGFB1 | 2.6 | 14.9 | 5.7 |
| TGFB2 | 0.8 | 4.6 | 6.0 | |
| TGFA | 7.4 | 59.7 | 8.1 | |
| ARTN | 0.4 | 9.0 | 21.7 | |
| Epidermal growth factors | EREG | 0.1 | 34.6 | 246.0 |
| NRG1 | 0.4 | 19.8 | 53.4 | |
| AREG | 2.7 | 354.7 | 133.9 | |
| HBEGF | 3.8 | 65.4 | 17.3 | |
| AREGB | 0.5 | 10.9 | 20.4 | |
| Dickkopf homologs | DKK1 | 1.1 | 91.4 | 82.6 |
| DKK3 | 0.3 | 7.3 | 27.9 | |
| Fibroblast growth factors | FGF2 | 0.2 | 1.8 | 7.7 |
| FGF11 | 1.3 | 8.3 | 6.2 | |
| Insulin growth factors | IGFL1 | 0.1 | 2.7 | 18.5 |
| Cholecystokinin | CCK | 0.2 | 2.8 | 18.4 |
| Endothelin | EDN1 | 0.2 | 7.5 | 31.7 |
| Galanin | GAL | 0.3 | 5.1 | 18.6 |
| Neuromedin | NMU | 1.0 | 11.7 | 11.4 |
| Peptide Y | PYY | 0.1 | 1.0 | 7.1 |
| Follistatin/inhibin | FST | 0.6 | 27.1 | 44.2 |
| INHBE | 0.1 | 0.7 | 7.1 | |
| Cytokines | IL1B | 1.8 | 20.9 | 11.7 |
| IL18 | 4.0 | 26.5 | 6.6 | |
| IFNE | 0.5 | 2.4 | 5.2 | |
| Adrenomedullin | ADM | 1.9 | 53.3 | 28.3 |
| Endothelin | EDN1 | 0.2 | 7.5 | 31.7 |
| Granulin | GRN | 6.2 | 37.6 | 6.1 |
| Jagged | JAG1 | 23.3 | 249.3 | 10.7 |
| Parathyroid hormone like hormone | PTHLH | 0.6 | 18.6 | 32.3 |
Genes identified by GATHER KEGG categories (Table 2, Table S3), Gene Ontology categories (Table 3, Table S5) and/or Canonical Pathways (Table 4, Table S6).
Receptors in the Human Airway Basal Cell-enriched Transcriptome.1
| Receptor family | Genes | Mean expression in differentiated epithelium | Mean expression in basal cells | Basal/differentiated epithelium expression ratio |
| EGF receptor | EGFR | 9.2 | 93.6 | 10.2 |
| TGFb receptor | TGFBR1 | 7.3 | 54.4 | 7.5 |
| TNF receptors | TNFRSF10B | 8.5 | 130.0 | 15.3 |
| TNFRSF10D | 1.5 | 23.0 | 15.3 | |
| TNFRSF12A | 2.7 | 69.4 | 25.5 | |
| TNFRSF10A | 1.1 | 5.9 | 5.4 | |
| Ephrin receptors | EPHB4 | 3.2 | 19.1 | 6.0 |
| EPHB2 | 0.8 | 6.0 | 7.7 | |
| Adrenergic receptor | ADRB2 | 6.6 | 38.4 | 5.9 |
| Leptin receptor | LEPR | 0.6 | 4.5 | 7.6 |
| Vasopressin receptor | AVPR1B | 0.4 | 1.9 | 5.3 |
| Histamine receptor | HRH1 | 0.5 | 2.3 | 5.1 |
| Serotonin receptor | HTR7 | 0.3 | 2.3 | 6.6 |
| G protein-coupled receptors | GPR37 | 0.5 | 3.0 | 5.9 |
| GPR87 | 5.5 | 47.4 | 8.7 | |
| GPR115 | 0.3 | 9.5 | 32.3 | |
| GPR126 | 1.5 | 15.0 | 10.2 | |
| GPR153 | 1.2 | 9.4 | 8.2 | |
| GPRC5A | 8.6 | 66.6 | 7.7 | |
| Light sensor | OPN3 | 4.7 | 26.6 | 5.6 |
| Cytokine receptors | IL13RA2 | 0.2 | 32.9 | 200.8 |
| IL1RL1 | 0.2 | 106.3 | 449.9 | |
| OSMR | 1.4 | 16.2 | 12.0 | |
| IL20RB | 2.3 | 67.3 | 28.7 | |
| IGF receptors | IGF2R | 11.3 | 57.8 | 5.1 |
| Tyrosine kinase | AXL | 5.7 | 34.6 | 6.0 |
| HGF receptor | MET | 30.9 | 195.3 | 6.3 |
| VEGF receptor | NRP1 | 0.2 | 2.7 | 13.0 |
| Opioid growth factor receptor | OGFRL1 | 2.4 | 14.8 | 6.2 |
| Platelet endothelial aggregation receptor | PEAR1 | 0.4 | 2.8 | 7.4 |
| LDL receptor | LDLR | 21.1 | 138.2 | 6.6 |
| Thrombin receptor | THBD | 1.7 | 53.5 | 31.5 |
| Protein C receptor | PROCR | 0.8 | 26.1 | 33.1 |
Genes identified by GATHER KEGG categories (Table 2, Table S3), Gene Ontology categories (Table 3, Table S5) and/or Canonical Pathways (Table 4, Table S6).
Ion Transport-related Genes in the Human Airway Basal Cell-enriched Transcriptome.1
| Symbol | Gene title | Mean expression in differentiated epithelium | Mean expression in basal cells | Basal/differentiated epithelium expression ratio |
| SLC7A5 | solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 | 0.6 | 201.0 | 314.7 |
| SLC7A11 | solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 | 0.8 | 116.5 | 141.2 |
| SLC16A1 | solute carrier family 16, member 1 (monocarboxylic acid transporter 1) | 0.3 | 23.8 | 69.8 |
| SLC16A4 | solute carrier family 16, member 4 (monocarboxylic acid transporter 5) | 0.5 | 18.4 | 34.5 |
| SLC4A5 | Solute carrier family 4, sodium bicarbonate cotransporter, member 5 | 0.1 | 4.1 | 30.5 |
| SLC3A2 | solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 | 2.9 | 84.6 | 29.1 |
| SLC22A3 | solute carrier family 22 (extraneuronal monoamine transporter), member 3 | 0.1 | 2.5 | 27.6 |
| SLC6A15 | solute carrier family 6 (neutral amino acid transporter), member 15 | 0.3 | 7.5 | 27.2 |
| KCNG1 | potassium voltage-gated channel, subfamily G, member 1 | 0.3 | 7.3 | 21.2 |
| SLC39A14 | solute carrier family 39 (zinc transporter), member 14 | 2.2 | 46.2 | 20.8 |
| SLC2A1 | solute carrier family 2 (facilitated glucose transporter), member 1 | 0.3 | 5.5 | 17.7 |
| SLC38A1 | solute carrier family 38, member 1 | 11.4 | 181.2 | 16.0 |
| ABCA12 | ATP-binding cassette, sub-family A (ABC1), member 12 | 0.6 | 7.1 | 12.8 |
| CLIC4 | chloride intracellular channel 4 | 1.3 | 15.8 | 12.2 |
| SLC35F2 | solute carrier family 35, member F2 | 1.2 | 13.5 | 11.7 |
| AMMECR1 | Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1 | 5.2 | 57.8 | 11.1 |
| SLC38A5 | solute carrier family 38, member 5 | 0.8 | 6.6 | 8.6 |
| SLC4A7 | solute carrier family 4, sodium bicarbonate cotransporter, member 7 | 0.8 | 7.0 | 8.3 |
| SLC25A15 | solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15 | 0.2 | 1.2 | 8.0 |
| KCNK6 | potassium channel, subfamily K, member 6 | 1.3 | 9.8 | 7.3 |
| SLC16A3 | solute carrier family 16, member 3 (monocarboxylic acid transporter 4) | 2.3 | 16.5 | 7.3 |
| SLC7A1 | solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 | 19.2 | 130.4 | 6.8 |
| SLC38A2 | solute carrier family 38, member 2 | 46.6 | 314.2 | 6.7 |
| SLC25A43 | solute carrier family 25, member 43 | 3.4 | 22.2 | 6.6 |
| KCMF1 | potassium channel modulatory factor 1 | 30.2 | 190.0 | 6.3 |
| SLC2A9 | Solute carrier family 2 (facilitated glucose transporter), member 9 | 0.4 | 2.3 | 6.2 |
| SLCO1B3 | solute carrier organic anion transporter family, member 1B3 | 0.4 | 2.6 | 6.1 |
| SLC9A1 | solute carrier family 9 (sodium/hydrogen exchanger), member 1 | 2.8 | 16.9 | 5.9 |
| KCNQ5 | potassium voltage-gated channel, KQT-like subfamily, member 5 | 0.3 | 1.9 | 5.5 |
| SLC6A8 | solute carrier family 6 (neurotransmitter transporter, creatine), member 8 | 3.5 | 19.2 | 5.5 |
| SLC35E4 | solute carrier family 35, member E4 | 0.3 | 1.5 | 5.5 |
| ABCC3 | ATP-binding cassette, sub-family C (CFTR/MRP), member 3 | 3.3 | 17.6 | 5.4 |
| SLC16A2 | solute carrier family 16, member 2 (monocarboxylic acid transporter 8) | 1.2 | 6.4 | 5.2 |
| KCTD9 | potassium channel tetramerisation domain containing 9 | 4.8 | 25.1 | 5.2 |
| SLC10A3 | solute carrier family 10 (sodium/bile acid cotransporter family), member 3 | 2.0 | 10.2 | 5.1 |
Genes identified by GATHER KEGG categories (Table 2, Table S3), Gene Ontology categories (Table 3, Table S5), and/or Canonical Pathways (Table 4, Table S6).
Transcription Factors in the Human Airway Basal Cell-enriched Transcriptome.1
| Symbol | Gene title | Mean expression in differentiated epithelium | Mean expression in basal cells | Basal/differentiated epithelium expression ratio |
| BNC1 | basonuclin 1 | 0.5 | 35.1 | 69.7 |
| ARNTL2 | aryl hydrocarbon receptor nuclear translocator-like 2 | 0.8 | 38.1 | 44.9 |
| FOSL1 | FOS-like antigen 1 | 0.7 | 22.9 | 30.7 |
| HMGA2 | high mobility group AT-hook 2 | 0.1 | 2.8 | 27.9 |
| SOX7 | SRY (sex determining region Y)-box 7 | 2.1 | 41.7 | 19.7 |
| ETV5 | Ets variant 5 | 0.3 | 6.0 | 18.3 |
| KLF7 | Kruppel-like factor 7 (ubiquitous) | 2.0 | 34.1 | 17.3 |
| HSF2BP | heat shock transcription factor 2 binding protein | 0.6 | 9.9 | 15.3 |
| ETS1 | v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) | 6.4 | 94.6 | 14.8 |
| SOX15 | SRY (sex determining region Y)-box 15 | 1.9 | 27.0 | 14.0 |
| CEBPG | CCAAT/enhancer binding protein (C/EBP), gamma | 4.3 | 54.0 | 12.6 |
| SNAI2 | snail homolog 2 (Drosophila) | 6.0 | 71.9 | 12.0 |
| FOXA2 | forkhead box A2 | 2.1 | 24.0 | 11.4 |
| ID3 | inhibitor of DNA binding 3, dominant negative helix-loop-helix protein | 1.7 | 19.3 | 11.1 |
| ETV4 | ets variant 4 | 0.3 | 3.5 | 10.8 |
| NPAS2 | neuronal PAS domain protein 2 | 0.4 | 4.7 | 10.7 |
| MXD1 | MAX dimerization protein 1 | 3.3 | 35.4 | 10.7 |
| ZNF185 | zinc finger protein 185 (LIM domain) | 8.7 | 89.2 | 10.3 |
| KLF9 | Kruppel-like factor 9 | 2.5 | 23.9 | 9.7 |
| KLF9 | Kruppel-like factor 9 | 2.5 | 23.9 | 9.7 |
| ZNF215 | zinc finger protein 215 | 0.3 | 2.9 | 9.5 |
| MYC | v-myc myelocytomatosis viral oncogene homolog (avian) | 9.6 | 90.1 | 9.4 |
| DR1 | down-regulator of transcription 1, TBP-binding (negative cofactor 2) | 3.0 | 28.2 | 9.3 |
| PAWR | PRKC, apoptosis, WT1, regulator | 5.2 | 47.8 | 9.2 |
| TAF1D | TATA box binding protein (TBP)-associated factor, RNA polymerase I, D, 41 kDa | 7.7 | 70.4 | 9.1 |
| CBX4 | chromobox homolog 4 (Pc class homolog, Drosophila) | 17.1 | 154.6 | 9.0 |
| TP63 | tumor protein p63 | 14.9 | 132.2 | 8.9 |
| HIF1α | hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | 30.0 | 258.6 | 8.6 |
| HES2 | hairy and enhancer of split 2 (Drosophila) | 1.6 | 13.2 | 8.5 |
| E2F7 | E2F transcription factor 7 | 2.5 | 20.7 | 8.2 |
| CCRN4L | CCR4 carbon catabolite repression 4-like (S. cerevisiae) | 0.4 | 3.3 | 8.1 |
| ZNF83 | zinc finger protein 83 | 1.3 | 10.0 | 8.0 |
Genes identified by GATHER KEGG categories (Table 2, Table S3), Gene Ontology categories (Table 3, Table S5) and/or Canonical Pathways (Table 4, Table S6). The top genes based on expression ratio are shown.